More specifically, GLP1R rs10305420 has been associated with response to exenatide in overweight patients with type 2 diabetes (Yu et al., 2019) and liraglutide in obese women with polycystic ovary syndrome (Jensterle et al., 2015). Here, GLP1R is linked to type 2 diabetes mellitus.